A clinical trial at Memorial Sloan Kettering Cancer Center showed promising results using immunotherapy as a first-line treatment for early-stage gastroesophageal cancers with mismatch repair deficiency. 71-year-old Maureen Sideris avoided traditional chemotherapy, radiation, and surgery, achieving remission after immunotherapy. The study, published in The New England Journal of Medicine, indicates immunotherapy could eliminate the need for surgery in many patients with this specific mutation, significantly improving quality of life. While not a cure-all, this approach offers substantial hope for those with mismatch repair deficient cancers.

Prepared by Olivia Bennett and reviewed by editorial team.